Press & News

People are different and so is their cancer, patients should be treated individually.

2cureX launches a Questions & Answers page on its website

March 26, 2018


2cureX AB (“2cureX”) hereby announce that the company today launched a Questions & Answers (Q&A) page (view here) on the Company’s website ( 2cureX is receiving several questions and comments from present and potentially future shareholders. 2cureX wants to make these questions and answers publicly available, and hopes that the site will become an active forum for people interested in individualized cancer treatment.

Questions and comments shall be mailed to

Certified Adviser
Sedermera Fondkommission is designated Certified Advisor For 2cureX.

For more information about 2cureX, please contact:
Ole Thastrup, CEO
Telecommunicationsfon: + 45 22 11 53 99

About 2cureX
2cureX has developed IndiTreat® (Individual Treatment Design) – a patented method for selecting the right drug for the right patient, thereby improving cancer treatment. Initially, IndiTreat® is targeted towards colorectal cancer; but the method is applicable to additional cancer. The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).